No Data
Hanshang Group Report for the Third Quarter of 2024
Hanshang Group\'s operating data announcement for the 1st to 3rd quarter of 2024
Hanshang Group's semi-annual report for 2024.
Hanshang Group's 2024 semi-annual report summary.
Hanshang Group (600774.SH): net income in the first half of the year was 8.5108 million yuan, a year-on-year decrease of 82.35%.
Hanshang Group (600774.SH) released its interim report for the first half of 2024 on August 15. During the reporting period, the company achieved revenue of 626 million yuan, a decrease of 10.74% year-on-year; the net profit attributable to shareholders of the listed company was 8.5108 million yuan, a decrease of 82.35% year-on-year; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was -4.0843 million yuan; basic earnings per share was 0.0288 yuan. The main factors affecting performance were the impact of centralized procurement and the increase in medicinal material prices on the subsidiary Dikang Pharmaceutical, leading to reduced profits; the subsidiary Dikang Traditional Chinese Medicine Pharmaceutical resumed production this year.
Hanshang Group (600774.SH), some directors, supervisors, executives, and management personnel have collectively increased their shareholding by 0.7442 million shares.
Hanshang Group (600774.SH) announced that as of the disclosure date of the announcement, some directors, supervisors, and management personnel of the company...
Earnings Working Against Hanshang Group Co., Ltd.'s (SHSE:600774) Share Price Following 26% Dive
